Keywords: Cipla, India, Patent ruling, Sutent, Pfizer, Cipla Medpro, M&A

Cipla prevails in Sutent patent dispute with Pfizer; puts hold on Cipla Medpro deal

Article | 12 February 2013

Print This

The Indian patent office has again ruled in favor of domestic drugmaker Cipla (BSE: 500087), reinstating its earlier decision to revoke ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in